Data capture is no longer the bottleneck, and whether the lag between a signal and a decision shrinks depends on signal design, AI governance, and vendor orchestration.
|Webcasts|December 11, 2019
Managing Signals in the Modern Pharmacovigilance Landscape
Author(s)Oracle Health Sciences
Recent research has emboldened the industry as it moves from traditional to hybrid studies with the promise of greater patient participation and patient access – despite this risk to overall study quality data was cited as the number one concern with decentralized trials. How can these risks be mitigated against? Live: Wednesday, Dec. 11, 2019 at 11am EST | 8am PST | 4pm GMT | 5pm CET On demand available after airing until Dec. 11, 2020. Register free
Register free:
Event Overview:
Signal management teams are entering a new world of pharmacovigilance, one where more big data sources are being used for signal detection and it’s becoming harder to sift through all that data manually. In this webcast, Oracle Health Sciences will review the best practices and new technologies for managing safety signals compliantly and efficiently, whether you’re part of a large organization that’s looking to improve existing processes or a small team that’s just starting to put a system in place. These include:
- User experience: making signals understandable and actionable for signal evaluators
- Signal documentation: traceability of decisions and actions in a regulatory inspection
- Lifecycle signal management: starting signaling activities during clinical trials and transitioning to post-marketing surveillance
- Signal detection methods: different approaches for different data sets
- Data mining algorithms: reducing the number of false positives and thus work for the signal evaluation tea
- Multimodal signal detection: aggregating signal statistics across multiple big data sets
- Neural signal detection: using artificial intelligence and deep learning to find new risks
- Predictive signal detection: cutting-edge research into future methodologies
Key Learning Objectives:
- Best Practices in Signal Management
- Insure compliance and efficiency
- Understand the true power of AI, Predictive Analytics and Data mining
Speaker: Michael Braun-Boghos, Senior Director, Safety Strategy, Oracle Health Sciences
Time and date: Wednesday, Dec. 11, 2019 at 11am EST | 8am PST | 4pm GMT | 5pm CET
On demand available after airing until Dec. 11, 2020.
Sponsor: Oracle Health Sciences
Register free:
Related to this article
In this Q&A, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, discusses what changes when AI is embedded across protocol strategy, data infrastructure, and workflow tools at once, where governance frameworks tend to fall short, and why CROs must orchestrate AI ecosystems rather than simply aggregate them.
In today’s ACT Brief, we examine what policy changes would help community and rural institutions join research, how Walmart is expanding clinical trial centers into three more states, and how FDA approved Ilumya for adults with active psoriatic arthritis.
The planned sites in Livonia, Las Vegas, and San Antonio would expand a partnership that places clinical research and health screenings inside Walmart stores.
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
In today’s ACT Brief, we examine why community and rural patients lack access to research as a care option, what makes AI assistants trustworthy in regulated trials, and how FDA draft guidance could let gene editing therapies cover patient-specific variants.
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.
In this video interview, Kent Thoelke, CEO of Paradigm Health, explains why patients in community and rural settings too often lack access to clinical research as a care option, and how closing that gap could improve outcomes and lower long-term costs.
Trending on Applied Clinical Trials Online
1
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
2
What Needs to Happen Beyond the Clinical Trial Modernization Act
3
From Signal to Action: Why Faster Trial Data Isn’t Producing Faster Decisions
4
Walmart and Care Access Plan Three More Clinical Trial Centers in Michigan, Nevada, and Texas
5